Avid Bioservices Inc (CDMO)

[patientlywaiting]

Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting




Companies:Peregrine Pharmaceuticals Inc.
Related Quotes
Symbol Price Change
PPHM 2.23 0.00

Press Release Source: Peregrine Pharmaceuticals On Monday February 28, 2011, 8:00 am
TUSTIN, CA--(Marketwire - 02/28/11) - Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM - News), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four studies investigating the company's lead phosphatidylserine (PS)-targeting clinical candidate bavituximab and other PS-targeting antibodies have been accepted for poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, April 2-6, 2011.

Abstracts Accepted at AACR:

Title: Targeting Phosphatidylserine to Improve Androgen Deprivation Therapy of Prostate Cancer
Authors: Yi Yin and Philip E. Thorpe
Presentation Time: Sunday, April 3, 2011, 1:00 - 5:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 26

Title: Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages
Authors: Xianming Huang, Dan Ye, and Philip E. Thorpe
Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 31

Title: Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity against Human Hepatocellular Carcinomas in Mice
Authors: Xiaoyun Cheng and Philip E. Thorpe
Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 30

Title: Monitoring Tumor Response to Chemotherapy by In Vivo Real-Time Imaging of Phosphatidylserine Targeting Antibodies
Authors: Jian Gong, Linda Him, Christopher Hughes, and Bruce Freimark
Presentation Time: Wednesday, April 6, 2011, 8:00 AM -12:00 PM ET
Location: Exhibit Hall A4-C, Poster Section 5

For additional information on the 102nd Annual Meeting of the AACR, please visit: http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011.aspx

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact:



Peregrine Contact:
Amy Figueroa
Peregrine Pharmaceuticals
[phone]
[e-mail]
Follow Yahoo! Finance on Twitter; become a fan on Facebook.

Related Headlines

Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting - Marketwire
PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers - EDGAR Online
Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Trial - Marketwire
Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Negative Metastatic Breast Cancer - Marketwire
Trial News Make Peregrine Pharmaceuticals Worth Watching - at Seeking Alpha
Related Message Boards